Toll-like receptor 4 is involved in the cell cycle modulation and required for effective human cytomegalovirus infection in THP-1 macrophages  by Arcangeletti, Maria-Cristina et al.




mariacrjournal homepage: www.elsevier.com/locate/yviroToll-like receptor 4 is involved in the cell cycle modulation and required
for effective human cytomegalovirus infection in THP-1 macrophagesMaria-Cristina Arcangeletti a,n, Diego Germini a, Isabella Rodighiero a, Prisco Mirandola b,
Flora De Conto a, Maria-Cristina Medici a, Rita Gatti b, Carlo Chezzi a, Adriana Calderaro a
a Department of Clinical and Experimental Medicine, University of Parma, Parma, Italy
b Department of Biomedical, Biotechnological and Translational Sciences, University of Parma, Parma, Italya r t i c l e i n f o
Article history:
Received 4 October 2012
Returned to author for revisions
6 November 2012
Accepted 28 January 2013




Toll-like receptor 422/$ - see front matter & 2013 Elsevier Inc. A
x.doi.org/10.1016/j.virol.2013.01.021
esponding author. Fax: þ39 521 993620.
ail address:
istina.arcangeletti@unipr.it (M.-C. Arcangeleta b s t r a c t
Suitable host cell metabolic conditions are fundamental for the effective development of the human
cytomegalovirus (HCMV) lytic cycle. Indeed, several studies have demonstrated the ability of this virus
to interfere with cell cycle regulation, mainly by blocking proliferating cells in G1 or G1/S. In the
present study, we demonstrate that HCMV deregulates the cell cycle of THP-1 macrophages (a cell line
irreversibly arrested in G0) by pushing them into S and G2 phases. Moreover, we show that HCMV
infection of THP-1 macrophages leads to Toll-like receptor 4 (TLR4) activation. Since various studies
have indicated TLR4 to be involved in promoting cell proliferation, here we investigate the possible role
of TLR4 in the observed HCMV-induced cell cycle perturbation. Our data strongly support TLR4 as a
mediator of HCMV-triggered cell cycle activation in THP-1 macrophages favouring, in turn, the
development of an efﬁcient viral lytic cycle.
& 2013 Elsevier Inc. All rights reserved.Introduction
Human cytomegalovirus (HCMV), the prototype member of
the b-herpesviruses (Mocarski and Courcelle, 2001), is a ubiqui-
tous and widespread agent that infects the majority of the
population during early childhood and then establishes a life-
long latency. It is the main viral cause of birth defects following
congenital infection and one of the most important opportunistic
pathogens leading to severe and even fatal diseases in ‘‘at-risk’’
categories of individuals, such as those with a deﬁcient immune
system due to iatrogenic (e.g. transplant patients) or acquired (e.g.
HIV-infected subjects, patients with cancer) causes (Alford and
Britt, 1996; Bosch et al., 2011; Cobbs et al., 2002; Pass, 2001;
Ramsay et al., 1991; Razonable and Paya, 2003). The multi-organ
involvement frequently observed in severe cases of HCMV dis-
eases, in particular those connected with the symptomatic reac-
tivation of the endogenous virus, is mainly due to its ability to
infect a variety of cell types, including different immune system
effectors, such as myeloid progenitors, dendritic cells, monocytes
and macrophages (Ro¨lle and Olweus, 2009; Slobedman et al.,
2004; So¨deberg-Naucler et al., 2001). In particular, monocytes are
important reservoirs of latent virus, while macrophages arell rights reserved.
ti).permissive to HCMV lytic infection and mediate its dissemination
into host tissues (Smith et al., 2004).
Another striking characteristic of HCMV, accounting for the
success of this agent as a pathogen, is its prominent capacity to
counteract host defence mechanisms, mainly by interfering with
intracellular signalling and inducing the transcription of cellular
genes involved in the activation of innate immunity, the inhibition
of apoptosis and the cell cycle regulation (Billstrom Schroeder
et al., 2002; Castillo and Kowalik, 2004; Compton et al., 2003;
Hertel and Mocarski, 2004; Salsman et al., 2012; Wolf et al., 2012).
With regard to the latter, it is known that HCMV can block the
progression of the cell cycle at G1 phase or during G1/S transition
in proliferating cells (Arcangeletti et al., 2011; Bain and Sinclair,
2007; Dittmer and Mocarski, 1997; Fortunato et al., 2002; Hertel
and Mocarski, 2004; Wiebusch et al., 2003). In contrast, conﬂuent
ﬁbroblast monolayers and human testicular embryonic carcinoma
cells (i.e. transiently or stably quiescent cell types, respectively)
have been described to re-enter the cell cycle upon HCMV infection
(Bresnahan et al., 1996; Jault et al., 1995; Sinclair et al., 2000; Song
and Stinski, 2005). Many in vitro studies investigating the possible
mechanism(s) through which HCMV might be able to perturb the
cell cycle have focussed on the possible role of viral immediate-
early proteins IEp72 and IEp86; these proteins are thought to
interact with important cellular activators of speciﬁc transcription
factors crucial for cell entry into S phase (Bain and Sinclair, 2007;
Hagemeier et al., 1994; Poma et al., 1996). Nevertheless, the above-
mentioned ability of HCMV to efﬁciently infect different kinds of
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might be able to co-opt alternative and/or additional mechanisms
to deregulate the cell cycle and promote its replication.
Paradoxically, a number of cellular functions exploited by
HCMV for an efﬁcient infection are also connected with the
activation of innate immunity, often triggered through the sti-
mulation of Toll-like receptors (TLR). The latter constitute the
main class of immune-sensor molecules capable of recognising a
broad range of pathogens, and an increasing body of literature
highlights the involvement of speciﬁc TLR during the infection of
different DNA and RNA viruses (Boheme and Compton, 2004;
Boehme et al., 2006; Cai et al., 2012; Cervera et al., 2007; Ducloux
et al., 2005; Gaur et al., 2011; Harwani et al., 2007; Kurt-Jones
et al., 2004; Lo¨fgren et al., 2010; Xagorari and Chlichlia, 2008;
Xia et al., 2008). Interestingly, other studies provide evidence
indicating novel functions of speciﬁc TLR in the regulation of
the cell cycle (Hasan et al., 2005, 2007).
Several HCMV gene products exhibiting extensive immuno-
modulatory effects have been identiﬁed, which result in the
evasion of host cell defences or the exploitation of immune
effectors for the improvement of viral infection, reactivation,
and dissemination (Mocarski, 2002a, 2002b). For instance,
HCMV-encoded IL-10 may profoundly attenuate host immunity,
facilitating the establishment and maintenance of a persistent
infection (Chang and Barry, 2010). Some important examples of
immune effectors co-opted by HCMV to its own beneﬁt include
monocyte-derived dendritic cells, rendered functionally impaired
by HCMV infection (Ro¨lle and Olweus, 2009), and inﬂammatory
cytokines, found to be activated in speciﬁc cell models via the
HCMV-induced stimulation of TLR2, which in turn increase the
severity of HCMV-induced disease (Compton et al., 2003). More-
over, it has been described that the reactivation of murine
cytomegalovirus from latency is dependent on the activation of
TLR4 (Xagorari and Chlichlia, 2008).
Considering the relevance of macrophages as a key innate
immune effector targeted by HCMV in vivo and the fact that this cell
type expresses the highest number of TLR subsets (Hornung et al.,
2002; Zarember and Godowski, 2002), the THP-1 macrophage cell
model used in this study provides an ideal opportunity to analyse the
effect of HCMV infection on the cell cycle of these resting cells and to
assess whether speciﬁc TLR are in some way involved in HCMV
infection. Here, we show that HCMV disrupts the cell cycle home-
ostasis of THP-1 macrophages and provide experimental data sup-
porting an important role of TLR4 signalling in mediating the HCMV-
induced cell cycle perturbation and effective HCMV infection.Results
Cell cycle progression in HCMV-infected THP-1 macrophages
The present study makes use of the THP-1 human monocytic cell
line that differentiates into macrophages following TPA treatment.
THP-1 macrophages therefore provide a suitable cell model, mimick-
ing the HCMV natural target, for studying the mechanisms through
which HCMV controls host cell metabolism to its own beneﬁt. Here,
we focus on cell cycle regulation and the possible involvement of
speciﬁc subsets of TLR during the HCMV infectious cycle.
In a preliminary series of control experiments (data not
shown), we conﬁrmed that THP-1 monocytes behave similarly
to the in vivo cells in that they are non-permissive to HCMV
infection, only becoming permissive following their differentia-
tion into macrophages; using ﬂow cytometry analysis and macro-
phage differentiation markers we also conﬁrmed that THP-1 cells
differentiate correctly.We next analysed whether the virus was able to rescue THP-1
macrophages (irreversibly withdrawn from the cell cycle) from G0;
indeed, over the course of a three-day-infection, using ﬂow cyto-
metry analysis to study the DNA distribution in the cell cycle phases
of uninfected and HCMV-infected THP-1 macrophages, we observed
that HCMV is able to cause a progressive re-entry of these cells into
the cell cycle, with an increased number of cells in S phase at 48 h
post-infection (p.i.) and in G2/M transition at 72 h p.i. (Fig. 1A, white
bars) compared to the mock infected cells (Fig. 1A, black bars).
Surprisingly, cell counts did not reveal any signiﬁcant increases in
the cell population at later time points (data not shown).
In order to verify that this effect was dependent on the presence
of an active virus, we concomitantly analysed the DNA distribution
in THP-1 macrophages infected with UV-inactivated virus (Fig. 1A,
grey bars). In this case, the results show a DNA distribution similar
to that of the uninfected cells (Fig. 1A, grey vs black bars). Mock
infected undifferentiated THP-1 cells were also included in this
analysis (Fig. 1, pale grey bars) in order to compare these
proliferating cells with the G0-arrested THP1 macrophages. The
full permissivity of the latter to the HCMV lytic cycle was also
conﬁrmed by analysing the viral transcript patterns (immediate-
early, early, early-late and late) at the considered times post-
infection, which were typical of a lytic program (Fig. 1B).
To conﬁrm the results obtained from cytoﬂuorimetry, which
demonstrated a virus-induced re-entry into the cell cycle with
increased S and G2/M phases, we next analysed the transcript
expression levels of cyclins E and A at the same time points as
those shown in Fig. 1 in order to evaluate their pattern during
(active and UV-inactivated) HCMV infection, as well as in mock
infected differentiated and undifferentiated THP-1 cells (Fig. 2).
Cyclin E is known to be required for the G1/S transition to occur,
and cyclin A is necessary for and mainly expressed in late S and
G2 and for the activation of mitosis-promoting factors (Hwang
and Clurman, 2005; Pagano et al., 1992; Vermeulen et al., 2003).
As shown in Fig. 2, the expression levels of cyclin E and A are
signiﬁcantly higher in active-virus-infected THP-1 macrophages
and, as expected, in mock infected undifferentiated THP-1 cells
compared to inactive-virus-infected and mock infected THP-1
macrophages, thus conﬁrming a true re-entering into the cell
cycle of HCMV-infected THP-1 macrophages.
TLR transcript levels in mock infected, active HCMV- and
UV-inactivated HCMV-infected THP-1 macrophages
Considering the ability of HCMV to activate speciﬁc effectors of
innate immunity in different cell models, in particular TLR
(Boehme et al., 2006; Xagorari and Chlichlia, 2008), we next
investigated whether TLR were co-opted in HCMV-infected THP-1
macrophages. To this end, we analysed the pattern of the TLR
transcripts known to be expressed in macrophages at 24, 48, and
72 h in active or UV inactivated virus-infected or mock infected
THP-1 macrophages (Fig. 3). The results show that TLR3, TLR4,
and TLR5 transcript levels increased during active HCMV infec-
tion, reaching a peak at 48–72 h p.i.; on the other hand, no
signiﬁcant expression differences were observed for TLR8 (Fig. 3),
TLR2 and TLR9 (data not shown) compared to the mock infected
or UV inactivated HCMV-infected cells. Interestingly, in the latter
experimental condition, only the TLR4 transcript level is upregu-
lated, supporting the hypothesis of a HCMV-induced TLR4 stimu-
lation occurring earlier than viral replication.
Effects of TLR3, TLR4 and TLR5 activation on the cell cycle
in uninfected THP-1 macrophages
Studies have demonstrated that TLR3, TLR4, and TLR5 are involved
not only in the classical role of innate immunity ‘‘sentinels’’, but also
Fig. 1. HCMV infection induces cell cycle progression in THP-1 macrophages. (A) THP-1 cell DNA distribution in the cell cycle phases under different experimental
conditions analysed by ﬂow cytometry. THP-1 macrophages were either infected with active HCMV (white bars) or UV-inactivated HCMV (grey bars), or mock infected
(black bars) and the distribution of DNA assessed at 24 h, 48 h, and 72 h p.i.. The DNA distribution of mock infected undifferentiated THP-1 cells was also analysed (pale
grey bars). Mean percentage values from three independent experiments are shown; error bars indicate standard deviations. Values were processed using GraphPad Prism
software. (B) RT-PCR ampliﬁcation patterns of immediate-early (‘‘IE1’’), early (‘‘DNA pol’’), early-late (‘‘pp65’’) and late (‘‘pp150’’) HCMV transcripts in THP-1 macrophages.
Infection was carried out for 24 h, 48 h and 72 h before total RNA extraction and RT-PCR reaction. The cellular GAPDH housekeeping gene was used as a control for PCR
loading; IE1 ampliﬁcation of the RNA extracts before reverse transcription (‘‘no-RT’’ control [IE1]) was performed to exclude the contribution of viral DNA to the signals.
Ampliﬁcation product lengths are shown on the right side of panel B.
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Considering this, together with the ﬁnding that the expression of
these speciﬁc TLR is up-regulated in infected THP-1macrophages (see
Fig. 3), we next investigated whether the activation of the above-
mentioned TLR was able to push uninfected THP-1 macrophages
(irreversibly blocked in G0) into the cell cycle.
To this end, a cytoﬂuorimetric analysis of the DNA distribution
of uninfected THP-1 macrophages was performed at 24, 48 and
72 h following their treatment with TLR3, TLR4, or TLR5 agonists:
polyinosinic:polycytidylic acid (Poly I:C), lipopolysaccharide (LPS)
or ﬂagellin (FLA), respectively (Fig. 4). The activation of these TLR
was checked by monitoring the transcription levels of speciﬁc
cytokines known to be increased following agonist treatment;
speciﬁcally, the transcript pattern of interleukin 8 (IL-8) was
analysed by RT-PCR to conﬁrm TLR3 activation, and interferon b
(IFN b) transcript was checked to verify TLR4 and TLR5 stimulation.
Interestingly, only the activation of TLR4 (Fig. 4, column ‘‘TLR4
[LPS]’’) led THP-1 macrophages to re-enter the cell cycle. It is also
noteworthy that the DNA distribution in the different phases of thecell cycle exhibited temporal kinetics similar to those observed in
HCMV-infected cells: following agonist treatment, an increased
quantity of cells could be observed in S phase and G2/M transition
at 48 and 72 h, respectively. On the other hand, TLR3 and TLR5
stimulation did not alter the DNA distribution, which remained
typical of resting cells.
Based on the aforementioned results, the next series of
experiments focussed on TLR4 and its possible involvement in
HCMV infection in THP-1 macrophages.
Effects of the TLR4 signalling pathway inhibition on cell cycle
progression in uninfected THP-1 macrophages
In order to conﬁrm that the observed LPS-induced cell cycle
activation could be attributed to TLR4 stimulation, two speciﬁc
inhibitors, CLI and NeutrAb, were used to block TLR4 signalling.
These antagonists act in different ways: CLI speciﬁcally blocks
signalling mediated by the TLR4 intracellular domain, inhibiting
the production of nitric oxide and pro-inﬂammatory cytokines,
Fig. 2. Up-regulation of cyclin E and A expression levels in HCMV-infected THP-1 macrophages. Cyclin E and A transcript expression in THP-1 macrophages at 24 h, 48 h
and 72 h p.i. was analysed by RT-PCR (infection with active or UV-inactivated HCMV, or mock infection); cyclin E and A expression in mock infected, undifferentiated THP-
1 monocytes were also assessed. The cellular GAPDH gene was ampliﬁed as a PCR loading control and before reverse transcription (‘‘no-RT’’ control [GAPDH]) to exclude
the contribution of cellular DNA to the signals. Ampliﬁcation product lengths are shown on the right side of panel. Similar results were obtained from two independent
experiments.
Fig. 3. TLR4 transcript is up-regulated in both active and UV-inactivated HCMV-infected THP-1 macrophages. The cells were infected with active or UV-inactivated virus or
mock infected for 24 h, 48 h and 72 h; TLR3, TLR4, TLR5 and TLR8 transcript patterns were analysed by RT-PCR. The cellular GAPDH gene was ampliﬁed as a PCR loading
control and before reverse transcription (‘‘no-RT’’ control [GAPDH]) to exclude the contribution of cellular DNA to the signals. Ampliﬁcation product lengths are shown on
the right side of panel. Comparable results were obtained from two independent experiments.
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external portion of the receptor, thus blocking TLR4 receptor
signalling by masking its binding site.
Uninfected THP-1 macrophages were treated with LPS alone, to
stimulate TLR4 or, alternatively, with LPS and one of the two TLR4
inhibitors, as detailed in the ‘‘Materials and methods’’ section; cell
DNA distribution was analysed by ﬂow cytometry at 0, 24 and 48 h
(Fig. 5). Stimulation of TLR4 with LPS (Fig. 5, white bars) typically
induced cell entry into S phase after 48 h, conﬁrming our previous
results (see Fig. 4). Conversely, the concomitant presence of either
of the TLR4 inhibitors (Fig. 5, grey bar: CLI; black bar: NeutrAb)
clearly prevented THP-1 macrophages from entering the cell cycle.
Changes in IFN b (TLR4 activation marker) transcript levels werealso monitored by RT-PCR in the three experimental conditions
(not shown).
IFN b transcript level pattern in TLR4-activated mock infected
or HCMV-infected THP-1 macrophages
The IFN b transcript expression pattern was monitored by RT-
PCR in mock infected and HCMV-infected THP-1 macrophages
(Fig. 6). Analysis was performed at 0, 24 and 48 h after TLR4
activation in mock infected (Fig. 6 ‘‘LPS’’) or active HCMV-infected
(Fig. 6 ‘‘HCMV’’) THP-1 macrophages; in both cases, cells were
untreated (Fig. 6 ‘‘LPS’’ and ‘‘HCMV’’) or treated with CLI (Fig. 6
‘‘LPSþCLI’’ and ‘‘HCMVþCLI’’, respectively) or NeutrAb (Fig. 6
Fig. 4. TLR4 signalling pathway activation induces uninfected THP-1 macrophages to re-enter the cell cycle. Flow cytometric analysis of DNA distribution was performed
at 24 h, 48 h and 72 h in uninfected THP-1 macrophages treated with polyinosinic:polycytidylic acid (‘‘Poly I:C’’; TLR3 agonist), lipopolysaccharide (‘‘LPS’’; TLR4 agonist),
or ﬂagellin (‘‘FLA’’; TLR5 agonist), as detailed in the ‘‘Materials and methods’’ section. Mean percentage values from three independent experiments are shown; error bars
indicate standard deviations. Bar charts were built up using GraphPad Prism software. TLR activation was checked by monitoring the transcription levels of cytokines
known to be stimulated following agonist treatment. Speciﬁcally, RT-PCR was used to assess the transcript levels of interleukin 8 (‘‘IL-8’’; product length: 260 bp) to test for
TLR3 activation, and interferon b (‘‘IFN b’’, 303 bp) to check that of TLR4 and TLR5.
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relevant data show that IFN b activation does occur following
HCMV infection in untreated differentiated THP-1 cells, and that
this activation is blocked in the presence of TLR4 inhibitors; thus,
IFN b activation is most likely a downstream effect of TLR4
stimulation.Effects of TLR4 signalling pathway inhibition on HCMV replication
To investigate whether TLR4 inhibition by CLI or NeutrAb
could have a negative impact upon the infection of THP-1
macrophages by HCMV (possibly connected with the lack of cell
cycle activation, as observed in uninfected cells; see Fig. 5), the
same inhibitors were used during HCMV infection to analyse their
effects on viral immediate-early gene expression and viral yield
(Fig. 7). IE1 transcript pattern was assessed at 24 and 48 h p.i. in
untreated cells (Fig. 7A a), or in the presence of CLI (Fig. 7A b) or
NeutrAb (Fig. 7A c); the percentage of cells expressing the viral
major IE proteins was analysed in the same experimental condi-
tions at 24, 48 and 72 h p.i. (Fig. 7B, bar graphs). Finally, the viral
yield from THP-1 macrophages was also assessed at 5, 6 and
7 days post-infection in the absence or presence of TLR4 inhibi-
tors (Fig. 7C, bar graphs), as detailed in the ‘‘Materials and
methods’’ section. The results show a signiﬁcant reduction in
HCMV IE1 transcript levels, IE proteins and viral yield following
treatment of THP-1 macrophages with TLR4 antagonists com-
pared to the untreated controls (Fig. 7A–C, compare control vs
treated cells).
In order to exclude the possibility that the observed effect
could be attributed to a decreased virus adsorption/entry in the
presence of TLR4 inhibitors, virus uptake was investigated (Sup-
plementary Figure 1) by analysing HCMV DNA (IE sequence) by
PCR at the beginning (‘‘0 h’’) and the end (‘‘2 h’’) of the adsorption
time in the absence (‘‘HCMV’’) and presence of each TLR4
inhibitor (‘‘HCMVþCLI’’; ‘‘HCMVþNeutrAb’’). No appreciable dif-
ferences in HCMV DNA are observed between the infection
control and treated cells, thus demonstrating that a differential
virus uptake is not responsible for the inhibition of IE (transcriptand protein) expression and for the viral yield decrease observed
in Fig. 7 upon treatment with TLR4 inhibitors.
Although cell viability was previously conﬁrmed to be unaf-
fected by the presence of the TLR4 antagonists (as described in
the ‘‘Materials and methods’’ section), to exclude the possibility
that inhibition of HCMV infection in THP-1 macrophages resulted
from antagonist-induced side effects, the same experimental
protocol was repeated in MRC5 ﬁbroblasts that are highly
permissive to HCMV infection and express neither TLR4 mRNA
nor protein (Friboulet et al., 2010; Matsumoto et al., 2002; Rudd
et al., 2005). As shown (Fig. 7D–F), neither of the antagonists
affected the IE1 transcript (Fig. 7D) nor protein levels (Fig. 7E) nor
viral yields (Fig. 7F) in MRC5 infected cells.
Effects of TLR4 signalling pathway inhibition on HCMV-induced
re-entry of THP-1 macrophages into the cell cycle
In the next series of experiments, differentiated THP-1 cells
were infected with HCMV for 24 (not shown), 48 and 72 h in the
absence (Fig. 8, column ‘‘HCMV’’) or presence of one of the two
selected TLR4 inhibitors (Fig. 8, columns ‘‘HCMVþCLI’’ and
‘‘HCMVþNeutrAb’’). Flow cytometry (both dot plot and histogram
representations are shown) was applied to analyse DNA distribu-
tion patterns in uninfected (black dots and histograms) and
HCMV infected (green dots and histograms) cells. Since the main
effects of infection on the cell cycle were most evident at 48 and
72 h, only the data obtained at these later times are shown.
The treatment of HCMV infected THP-1 macrophages with
TLR4 antagonists resulted in a signiﬁcantly reduced concentration
of infected cells (expressing viral IE proteins) at both 48 and 72 h
p.i. (Fig. 8, columns ‘‘HCMVþCLI’’ and ‘‘HCMVþNeutrAb’’, IEþ
percentages in the dot plot graphics) compared to that observed
in HCMV infected cells in the absence of antagonists (Fig. 8,
column ‘‘HCMV’’, IEþ percentages). As can be deduced from the
the relative mean percentage values for G0/G1, S and G2/M
shown in the top right-hand corner of each histogram, it is once
again evident that HCMV drives quiescent THP-1 cells into the S
and G2 phases of the cell cycle (Fig. 8, column ‘‘HCMV’’, green
histograms and green dots), since a DNA distribution pattern
Fig. 5. Inhibition of the TLR4 pathway prevents uninfected THP-1 macrophages
from re-entering the cell cycle. Flow cytometric analysis of the distribution of cell
DNA was performed to assess the effect of two speciﬁc TLR4 antagonists (CLI and
NeutrAb) on the cell cycle activation observed upon TLR4 stimulation with LPS.
Analysis was performed at 0 h, 24 h and 48 h following either TLR4 activation
alone (‘‘LPS’’) or concomitant treatment with CLI (‘‘LPSþCLI’’) or NeutrAb
(‘‘LPSþNeutrAb’’), as detailed in the ‘‘Materials and methods’’ section. Changes
in IFN b (a marker of TLR4 activation) transcript levels were also monitored by
RT-PCR (not shown). Mean percentage values from three independent experi-
ments are shown; error bars indicate standard deviations. Values were processed
using GraphPad Prism software.
Fig. 6. Up-regulation of IFN b transcript expression in TLR4-activated mock
infected or HCMV-infected THP-1 macrophages. The pattern of IFN b transcript
expression was monitored by RT-PCR in mock infected and HCMV-infected THP-1
macrophages. Analysis was performed at 0 h, 24 h and 48 h after TLR4 activation
(‘‘LPS’’) in mock infected or active HCMV-infected (‘‘HCMV’’) THP-1 macrophages;
in both cases, cells were untreated (‘‘0 h’’) or treated with CLI (‘‘LPSþCLI’’ and
‘‘HCMVþCLI’’, respectively) or NeutrAb (‘‘LPSþNeutrAb’’ and ‘‘HCMVþNeutrAb’’,
respectively), as detailed in the ‘‘Materials and methods’’ section. The cellular
GAPDH housekeeping gene was used as PCR loading control. Similar results were
obtained from two independent experiments.
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34.1% and 34% of cells are in S phase in green graphics at 48 and
72 h p.i., respectively), corroborating the results presented in
Fig. 1A. On the other hand, in THP-1 macrophages infected with
HCMV and treated with CLI or NeutrAb, cell cycle activation is
signiﬁcantly reduced, as observed in the corresponding graphicsand conﬁrmed by the S phase percentages (10.1% and 13.1% in the
presence of CLI and 13.1% and 7.9% in the presence of NeutrAb at
48 and 72 h, respectively).Discussion
Viruses have evolved a variety of mechanisms to efﬁciently
infect their hosts, which mainly involve the interference with host
cell regulation systems and signalling pathways (Bruggeman,
2007; Gale et al., 2000; Mirandola et al., 2006). The strategies
employed by HCMV are numerous and can vary drastically
depending on whether it resides latent within a host cell or has
entered its lytic cycle (Adler and Sinzger, 2009; Arrode and
Devrinche, 2003; Lunardi et al., 2005; Pass, 2001). During latent
infection, although the HCMV genome remains stably present,
it is mostly unexpressed and its impact on the host cell metabo-
lism is quite restricted (Slobedman et al., 2004). In the case of
lytic infection, the virus competes for and exploits different
functions of the host cell in order to develop efﬁcient infection
and produce viral progeny (Hertel and Mocarski, 2004).
The goal of the present study was to extend our knowledge of the
cellular mechanisms co-opted by HCMV that enable it to carry out
productive infection and create the ideal conditions for its replication
in a resting cell, such as a macrophage model. The THP-1 macro-
phages, mimicking one of the major strategic targets exploited by
HCMV in vivo, represent an ideal paradigm in which to study HCMV
infection. Indeed, the differentiation of peripheral blood monocytes
into macrophages provides the latent virus with a cell environment
within which it is able to sustain a lytic infection, favouring its
dissemination into host tissues (Mendelson et al., 1996; Taylor-
Wiedeman et al., 1994). In the monocyte-macrophage system, a tight
correlation between cellular differentiation and HCMV reactivation
from latency is likely to exist; speciﬁcally, the post-mitotic stage that
initiates the maturation of monocytes into macrophages is thought to
stimulate the viral gene expression that leads to productive infection
(Sinclair and Sissons, 2006).
Fig. 7. Inhibition of HCMV replication in THP-1 macrophages following treatment with TLR4 speciﬁc antagonists. (A, D) Viral IE1 transcript expression in HCMV-infected
(A) THP-1 macrophages or (D) MRC5 ﬁbroblasts analysed by RT-PCR at 24 h and 48 h p.i. following (a) mock treatment or (b) treatment with CLI or (c) NeutrAb; the
housekeeping GAPDH gene transcript was analysed in parallel as a PCR loading control. (B, E) Effects of CLI or NeutrAb treatment on viral major IE protein expression in
HCMV-infected (B) THP-1 macrophages or (E) MRC5 ﬁbroblasts. Cells were infected with HCMV in the absence (white bars) or presence of either CLI (black bars) or
NeutrAb (grey bars), then ﬁxed at 24 h, 48 h or 72 h p.i. Immunoﬂuorescence staining and positive cell counts were performed as detailed in the ‘‘Materials and methods’’
section. (C, F) Effects of TLR4 pathway inhibition on (C) THP-1 macrophage- or (F) MRC5 ﬁbroblast-derived HCMV yield. Viral progeny evaluation was performed as
described in the ‘‘Materials and methods’’ section. Mean percentage values from two independent experiments are shown (B, E and C, F); error bars indicate standard
deviations. Bar charts were built up using GraphPad Prism software.
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permissive to HCMV infection; in fact, as shown here, the viral
transcript expression pattern is representative of all the phases of
HCMV lytic cycle and the viral progeny is also produced, thus
conﬁrming previous data from our group (Ioudinkova et al., 2006).
When considering the possible strategies adopted by HCMV to
productively infect these cells, it is important to take into account
the following three important points. First of all, as in the in vivo
situation, THP-1 macrophages are irreversibly withdrawn from
the cell cycle. One might therefore expect that the virus would
not ﬁnd an adequate supply of deoxyribonucleotides and cofac-
tors (abundant in late G1 and G1/S of cycling cells) necessary for
the efﬁcient replication of its genome; nevertheless, it has been
demonstrated that HCMV can efﬁciently infect macrophages
in vivo (Castillo and Kowalik, 2004). The second important point
deals with the ability of this virus to manipulate the cell cycle,
keeping in mind that in cycling cells HCMV is able to block thecell cycle, mainly in late G1 phase or G1/S transition, by con-
comitantly abolishing cellular DNA replication (Arcangeletti et al.,
2011; Bain and Sinclair, 2007; Dittmer and Mocarski, 1997;
Fortunato et al., 2002; Hertel and Mocarski, 2004). The third
important point concerns HCMV infection of quiescent cells, such
as the THP-1 macrophages used in this study. A previous study
(Sinclair et al., 2000) has described the ability of HCMV to push
G0 cells into early S phase in a quiescent human embryo
teratocarcinoma cell line (NT2D1).
To this regard, it was of crucial importance to ascertain
whether this viral agent had developed the capacity to circum-
vent the lack of S phase components in a strategically important
resting cell in vivo, such as the macrophage.
To this end, the ﬁrst aim of this study was to check whether
HCMV could alter the THP-1 cell cycle to its own advantage. Our
results demonstrate that HCMV is indeed able to induce these
cells to re-enter the cell cycle, with a gradual increase in the
Fig. 8. TLR4 signalling pathway inhibition signiﬁcantly reduces the HCMV-driven cell cycle activation in THP-1 macrophages. The effect of two speciﬁc TLR4 antagonists
(CLI and NeutrAb) upon HCMV-induced cell cycle activation was analysed by ﬂow cytometry at 48 h and 72 h p.i. The cellular DNA and viral IE antigen distributions of
infected cells in the absence of TLR4 antagonists (‘‘HCMV’’) was compared to that of infected cells treated with either CLI (‘‘HCMVþCLI’’) or NeutrAb (‘‘HCMVþNeutrAb’’).
Cells were ﬁxed at the indicated times p.i. and stained with a monoclonal antibody speciﬁc for HCMV major IE gene products. Green dots in the dot plot representation and
green histograms indicate cells positive for viral IE proteins, the percentages of which are displayed in the dot plots; black dots and black histograms represent uninfected
cells. The relative mean percentage values for G0/G1, S and G2/M from three independent experiments are shown in the top right-hand corner of each histogram.
(For interpretation of the references to color in this ﬁgure legend, the reader is referred to the web version of this article.)
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to an increase in the number of cells. In order to expand these
results, we analysed the transcript pattern levels of cyclin E
(required for G1/S transition) and A (necessary for the late S
and G2 and for the activation of mitosis-promoting factors)
(Hwang and Clurman, 2005; Pagano et al., 1992, Vermeulen
et al., 2003), and found that they are signiﬁcantly increased in
active-virus-infected THP-1 macrophages.
These data support the notion of a virus-induced cell cycle
activation that, in contrast to that observed in the NT2D1 model
(Sinclair et al., 2000) leading to the early S phase activation, goes
through the late S and G2 phases.
Of the possible mechanisms that HCMV might exploit to
activate the cell cycle in THP-1 macrophages, the present study
focussed on the potential involvement of the TLR family on the
basis of a series of notions already presented in the literature.
First of all, macrophages are among the most important effectors
of the innate immune response against pathogens and they
constitute one of the cell types expressing the highest number
of TLR subtypes (Hornung et al., 2002; Zarember and Godowski,
2002). Second, not only does HCMV possess different strategies to
evade the host immune defences, but it is also able to activate and
exploit host immune responses (particularly the inﬂammatory
process) to increase its virulence (Boheme and Compton, 2004;
Compton et al., 2003; Kovacs et al., 2007; Mocarski, 2002a, 2002b;
Varani and Landini, 2011). Third, and most importantly, speciﬁc
TLR receptors have been described not only for their classical
function in the immune response, but also for having a role in cell
cycle regulation, with particular emphasis placed upon TLR3,
TLR4 and TLR5 (Hasan et al., 2005, 2007).
In the present study, we show that active HCMV-infected
THP-1 macrophages present a signiﬁcant increase in the tran-
scription levels of the genes encoding TLR3, TLR4 and TLR5proteins compared to uninfected controls. These results lie in
accordance with the observations made by others investigating
different cell models and/or viruses (Iversen et al., 2009; Jiang
et al., 2008; West and Damania, 2008). The presence of cross-talk
between different TLR could explain how the expression of more
than one TLR subtype may be inﬂuenced at the same time
(Palazzo et al., 2008), as observed in the present work.
An important ﬁnding of this study is that in uninfected THP-1
macrophages only TLR4 activation is connected with re-entry into the
cell cycle. Furthermore, inhibition of the TLR4-mediated signalling
pathway drastically inhibited the efﬁciency of HCMV infection in this
in vitro model. Interestingly, it has been shown that TLR4 activation
leads to pulmonary reactivation of murine cytomegalovirus in mice
and that inhibition of TLR4 signalling by a monoclonal antibody was
able to block this reactivation (Xagorari and Chlichlia, 2008).
Moreover, our data demonstrate that TLR4 inhibition signiﬁ-
cantly reduces the virus-induced activation of the cell cycle in
HCMV-infected THP-1 macrophages, leading to the hypothesis
that an interaction between HCMV and TLR4 exists and, consider-
ing the cell membrane location of this receptor, that it could be
part of a receptorial or co-receptorial complex exploited by HCMV
in THP-1 macrophages. In support of this hypothesis, here we
demonstrate that an increase in the TLR4 transcription level (but
not TLR3 and TLR5) also occurs with the UV-inactivated HCMV,
in accordance with data obtained by Boehme et al. (2006),
studying TLR1/TLR2 heterodimer in a HCMV-infected
ﬁbroblast model.
Nevertheless, in this macrophage-like model we also demon-
strate that the expression of the IFN b transcript is signiﬁcantly
increased during THP-1 macrophage infection with active HCMV
(with levels and a time course comparable to those observed in
TLR4-activated uninfected cells) and that the presence of TLR4
speciﬁc inhibitors interfere with this expression, thus supporting
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downstream effect of TLR4 activation.
Taking into account data showing that once stimulated, this
receptor may become internalised (Husebye et al., 2006), and that
the internalisation of TLR4 into the endosomal network is
required to regulate type I IFN expression (Chiang et al., 2011;
Zanoni et al., 2011), the present set of data let us hypothesise that,
not only could TLR4 form part of a receptorial or co-receptorial
complex for HCMV in THP-1 macrophages, but that it might also
be involved in later stages of infection, such as the internalisation
process and in events connected with cell cycle activation. This is
also coherent with our ﬁnding that only active HCMV leads to the
activation of the cell cycle in THP-1 macrophages.
Concerning the possible connection between cell cycle dereg-
ulation and IFN production, the latter has been described to
inﬂuence cell cycle progression by prolonging the S phase and
G2/M transition, whilst inhibiting cell proliferation (Katayama
et al., 2007). Accordingly, here we observe a similar effect of
HCMV infection upon the cell cycle in THP-1 macrophages, with a
gradual increase in the quantity of DNA residing in S and G2/M
phases, in the absence of concomitant cell proliferation.
Work in our laboratory is currently in progress to elucidate the
role of TLR4 internalisation and interferon b production in the
observed cell cycle modulation induced by HCMV in THP-1
differentiated cells.
In conclusion, using a human macrophage model closely
related to the HCMV natural target in vivo, the present study
provides the ﬁrst evidence demonstrating virus-induced activa-
tion of the cell cycle which, in turn, requires TLR4 activation.
These results are relevant as they are able to account for the
efﬁcient productive infection of these important cell targets and
explain how they may be exploited by HCMV to favour its tissue
dissemination.
Whilst many questions remain open, our ﬁnding that a sig-
niﬁcant reduction in HCMV lytic replication occurs in this human
macrophage model, following TLR4 inhibition, unveils novel routes
for identifying innovative targets for prophylactic and/or thera-
peutic approaches to counteract HCMV replication.Materials and methods
Cell culture
Cultures of the monocytic cell line THP-1 (‘‘Istituto Zooproﬁ-
lattico Sperimentale della Lombardia e dell’Emilia-Romagna’’)
were maintained in suspension in RPMI 1640 medium, supple-
mented with 1% L-glutamine, 1% sodium pyruvate, 50 mM b-
mercaptoethanol, 10% foetal bovine serum (FBS) and antibiotics
(100 U/ml penicillin and 100 mg/ml streptomycin). Cell differen-
tiation into macrophages was induced by adding 80 nM 12-O-
tetradecanoylphorbol-13-acetate (TPA) (Sigma-Aldrich) to the
medium for 48 h to obtain fully adherent cells.
Monolayer cultures of MRC5 human embryo lung ﬁbroblasts
(American Type Culture Collection, ATCC; CCL-171) were grown
in Earle’s modiﬁed Minimum Essential Medium (E-MEM), supple-
mented with 1% L-glutamine, 1% non-essential amino acids, 1 mM
sodium pyruvate, 10% FBS and antibiotics (100 U/ml penicillin,
100 mg/ml streptomycin). Cell culture medium and supplements
were obtained from PAA (The Cell Culture Company).
Virus strain, titration and cell infection
HCMV reference Towne strain (ATCC VR-977) was propagated
in MRC5 cells; viral infectious titre was determined as previously
described (Arcangeletti et al., 2003).THP-1 monocytes were grown and differentiated in 6-well micro-
plates at the concentration of 3106 cells/well. After differentiation,
THP-1 cells were washed in E-MEM without FBS, then infected with
HCMV Towne at amultiplicity of infection (m.o.i.) of 2 plaque forming
units (PFU)/cell. Virus adsorption was performed by centrifugation at
700 g for 45min then incubation at 37 1C for 75 min. Subsequently,
the virus inoculum was removed and replaced with 10% RPMI. The
infected cells were incubated at 37 1C for the indicated times. HCMV
infection of MRC5 ﬁbroblasts was carried out at an m.o.i. of 0.2.
Viral yield analysis was performed as already described
(Ioudinkova et al., 2006), by using a 10-fold lower m.o.i. for the
infection of THP-1 macrophages (m.o.i. of 0.2) and MRC5 ﬁbro-
blasts (m.o.i. of 0.02), in the presence or the absence of TLR4
antagonists. Brieﬂy, at the indicated days p.i., THP-1 and MRC5
cells supernatants were collected, centrifuged at low speed
(7,500 g) for 10 min then used to infect MRC5 ﬁbroblasts. HCMV
yield titration was evaluated using the immunoﬂuorescence tech-
nique (as described in the ‘‘Indirect immunoﬂuorescence’’ section).
Virus inactivation
For the UV inactivation of HCMV Towne, an aliquot of virus
was diluted into 1 ml of E-MEMwithout FBS (to obtain an m.o.i. of
2 for the infection of 3106 THP-1 macrophages) and transferred
to a 3 cm Petri dish. The viral suspension was placed on ice and
UV-irradiated for 2 h at a distance of 5 cm from the UV lamp. The
UV-inactivated virus did not replicate or produce any detectable
levels of IE gene products (data not shown).
Treatment with speciﬁc agonists of the TLR3, TLR4, and TLR5
signalling pathways
Differentiated THP-1 cells, seeded in 6-well plates at the
concentration of 3106 cells/well, were treated for 6 h with
one of the following: a synthetic dsRNA analogue (Poly I:C high
molecular weight, InvivoGen) acting as a TLR3 agonist, at the ﬁnal
concentration of 1 mg/ml; lipopolysaccaride (Ultra Pure E. coli K12
LPS, InvivoGen) a TLR4 agonist, at the ﬁnal concentration of 1 mg/
ml; or ﬂagellin (Salmonella typhimurium FLA, InvivoGen), a TLR5
agonist, at the ﬁnal concentration of 500 ng/ml. Following treat-
ments, TLR agonists were withdrawn and cell monolayers were
HCMV-infected or mock-infected for the established times. Cell
viability was checked using trypan blue (Sigma-Aldrich) and
chromatin staining by DAPI (described in the ‘‘Antibodies and
ﬂuorescent dyes’’ section).
Treatment with the TLR4 antagonist CLI
Uninfected THP-1 macrophages were pre-treated for 1 h with
1 mg/ml CLI (InvivoGen), a cycloexene derivative known to antag-
onise TLR4 activation, and then treated with lipopolysaccharide
(LPS) together with 10 mg/ml CLI for 6 h. After the latter incuba-
tion time, the TLR4 antagonist was maintained in the cell culture
medium at the concentration of 100 ng/ml for the established
times. The same protocol was applied to HCMV infected cells. Cell
viability was assessed as stated above.
Treatment with a neutralising polyclonal antibody directed against
TLR4 (NeutrAb)
Uninfected THP-1 macrophages were pre-treated with a neu-
tralising polyclonal antibody directed against TLR4 (NeutrAb,
InvivoGen) for 1 h at the concentration of 10 mg/ml. Following
pre-treatment, 5 mg/ml NeutrAb was kept in the cell culture
medium for the duration of LPS treatment, then maintained in
the cell culture medium at the concentration of 2.5 mg/ml for the
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infected cells. Cell viability was assessed as stated above.
RNA isolation and RT-PCR assay
Total RNA was extracted from cells using the NucleoSpins RNA
II kit according to the manufacturer’s instructions (Macherey-
Nagel). Protein and DNA contaminations were checked in RNA
extracts using an Eppendorf biophotometer (absorbance at 260 and
280 nm and extinction coefﬁcient, respectively). Futhermore, to
conﬁrm the absence of DNA contamination, PCR for viral (IE1) or
cellular (glyceraldehyde-3-phosphate dehydrogenase [GAPDH])
genes were done on not-retrotranscribed RNA extracts.
Template RNAs were then reverse transcribed using the Rever-
tAid ﬁrst strand cDNA synthesis kit (Fermentas). The obtained cDNA
was subjected to PCR ampliﬁcation using the following: speciﬁc
primers for viral transcripts IE1 (303 bp), DNA pol (237 bp), pp65
(213 bp) and pp150 (206 bp) (Ioudinkova et al., 2006); speciﬁc
primers for Cyclin E (F: 50-GTCCTGGCTGAATGTATACATGC-30; R:
50-CCCTATTTTGTTCAGACAACATGGC-30, 415 bp), Cyclin A (F: 50-
GTCACCACATACTATGGACATG-30; R: 50-AAGTTTTCCTCTCAGCACT-
GAC-30, 300 bp), TLR3 (F: 50-AGGAACTCCTTTGCCTTGGT-30; R: 50-
CAAGACCCTCCAACATGTCA- 30, 172 bp), TLR4 (F: 50-AATCCCCT-
GAGGCATTTAGG-30; R: 50-CACAGCCACCAGCTTCTGTA-30 212 bp),
TLR5 (F: 50-GTCTTGGATATAACTCATAACA-30; R: 50-GAACTTTGT-
GACTGTGAGGA-30 273 bp) and TLR8 (F: 50-TCAACAAATCCGCACTT-
GAA-30; R: 50-CCTCTTTGATCCCCAGGACT-30 181 bp); speciﬁc
primers for interferon b (303 bp) (Opitz et al., 2006) and interleukin
8 (260 bp) (Lihn et al., 2003). The speciﬁcity of every couple of
primers was controlled before use by means of ampliﬁcation
reactions with a mock sample (water) and agarose gel electrophor-
esis. A GAPDH fragment of 242 bp (Ioudinkova et al., 2006) was
ampliﬁed as a sample loading calibration control.
Antibodies and ﬂuorescent dyes
For conventional immunoﬂuorescence, a puriﬁed monoclonal
antibody (Mab clone E13; working dilution 1:30) speciﬁc for the
common epitope encoded by exon 2 of the immediate early (IE)
major products (72 and 86 kDa proteins) (Argene) was used as
primary antibody. A monoclonal anti-rat IgG1-K antibody (AbD
Serotec) was used as negative control for ﬂow cytometry analysis.
The immunoreactions were revealed by Alexa-Fluor ﬂuorescein
isothiocyanate (FITC)-conjugated goat anti-mouse IgG (HþL)
(Invitrogen; working dilution 1:500) to detect viral antigens.
The ﬂuorescent compound with high afﬁnity for DNA 40,60-
diamin-2-phenylindole chlorhydrate (DAPI-385 nm, Sigma-
Aldrich: working dilution 1:2000) was also used as chromatin
marker. Working dilutions were prepared in 0.2% bovine serum
albumin (BSA) in phosphate buffered saline (PBS: 7 mM Na2H-
PO4,1.5 mM KH2PO4, pH 7.4, 137 mM NaCl, 2.7 mM KCl). Propi-
dium iodide (PI; 10 mg/ml) was used to stain DNA for
cytoﬂuorimetric analyses. All chemicals were from Sigma-Aldrich.
Indirect immunoﬂuorescence
Differentiated THP-1 cells were gently ﬁxed with methanol at
20 1C for 10 min for the detection of HCMV IE proteins, and then
stained and analysed as previously described (Arcangeletti et al.,
2003). To establish the number of IE-positive cell nuclei, 10 ﬁelds
per dish were counted and positive cells expressed as mean
percentages of the total cell number per ﬁeld (evaluated by DAPI
counterstaining of nuclei).
For THP-1- and MRC5- derived viral yield titration, the number
of IE-positive ﬁbroblasts was counted at 24 h p.i. and expressed aspercentage value of the total number of cells per dish (evaluated
by DAPI counterstaining of nuclei).
Indirect immunoﬂuorescence for ﬂow cytometry analysis
At the established times, THP-1 macrophages were trypsi-
nised, harvested and centrifuged at 800 g for 10 min at room
temperature. The cells were treated as previously described
(Arcangeletti et al., 2011). Brieﬂy, the supernatant was discarded
and the pellet resuspended in 0.6 ml PBS and 1.4 ml ethanol 100%
(ice-cold ethanol 70%) added in a drop-wise manner, then ﬁxed/
permeabilised overnight at 20 1C. Cells were subsequently
centrifuged at 800 g for 10 min at room temperature, the
supernatant discarded and the pellet resuspended in 0.5 ml PBS.
Cells were pelleted again and immunostained for 30 min at room
temperature in the dark using a primary antibody directed
against HCMV immediate early major products. Cells were then
rinsed in wash buffer (0.5% BSA-PBS) and centrifuged; the pellet
was resuspended in the appropriate dilution of Alexa-Fluor FITC-
conjugated goat anti-mouse IgG secondary antibody and incu-
bated for 30 min at room temperature in the dark. Cells were
rinsed in wash buffer, pelleted and resuspended in PBS containing
PI (10 mg/ml) and RNase (100 mg/ml) and incubated for 30 min at
room temperature. Control cells were stained using a monoclonal
anti-rat IgG1-K.
Flow cytometry
THP-1 cells, prepared as described above, were analysed using
the EPICSs XL-MCL cytometer (Beckman Coulter). DNA content
and viral parameters in the different cell cycle phases were
examined using Expo32 Software (Beckman Coulter). Peaks cor-
responding to G0/G1, S and G2/M were obtained excluding
doublets and cell debris by FL3lin/RATIO and FS/FL3log dot plot
analysis, respectively (Gobbi et al., 2009).Acknowledgements
This study was supported by the ‘‘FIL 2009’’ grant from the
University of Parma, Italy, and the Italian Scientiﬁc Research Fund
‘‘PRIN 2008’’.Appendix A. Supporting information
Supplementary data associated with this article can be found in
the online version at http://dx.doi.org/10.1016/j.virol.2013.01.021.References
Adler, B., Sinzger, C., 2009. Endothelial cells in human cytomegalovirus infection:
one host cell out of many or a crucial target for virus spread? Thromb.
Haemost 102 (6), 1057–1063.
Alford, C.A., Britt, W.J., 1996. Cytomegalovirus. In: Knipe, D., Howley, P. (Eds.), Fields
Virology, third ed. Lippincott-Raven Publishers, Philadelphia, pp. 2493–2534.
Arcangeletti, M.C., De Conto, F., Ferraglia, F., Pinardi, F., Gatti, R., Orlandini, G.,
Calderaro, A., Motta, F., Medici, M.C., Valcavi, P., Razin, S.V., Chezzi, C., Dettori,
G., 2003. Human cytomegalovirus proteins pp65 and IEp72 are targeted to
distinct compartments in nuclei and nuclear matrices of infected human
embryo ﬁbroblasts. J. Cell. Biochem. 90 (5), 1056–1067.
Arcangeletti, M.C., Rodighiero, I., Mirandola, P., De Conto, F., Covan, S., Germini, D.,
Razin, S., Dettori, G., Chezzi, C., 2011. Cell-cycle-dependent localization of
human cytomegalovirus UL83 phosphoprotein in the nucleolus and modula-
tion of viral gene expression in human embryo ﬁbroblasts in vitro. J. Cell.
Biochem. 112 (1), 307–317.
Arrode, G., Devrinche, C., 2003. Dendritic cells and HCMV cross-presentation. Curr.
Top. Microbiol. Immunol. 276, 277–294.
M.-C. Arcangeletti et al. / Virology 440 (2013) 19–30 29Bain, M., Sinclair, J., 2007. The S phase of the cell cycle and its perturbation by
human cytomegalovirus. Rev. Med. Virol 17 (6), 423–434.
Billstrom Schroeder, M., Christensen, R., Worthen, G.S., 2002. Human cytomega-
lovirus protects endothelial cells from apoptosis induced by growth factor
withdrawal. J. Clin. Virol. 25 (Suppl. 2), 149–157.
Boheme, K.W., Compton, T., 2004. Innate sensing of viruses by toll-like receptors. J.
Virol. 78 (15), 7867–7873.
Boehme, K.W., Guerrero, M., Compton, T., 2006. Human cytomegalovirus envelope
glycoproteins B and H are necessary for TLR2 activation in permissive cells. J.
Immunol 177 (10), 7094–7102.
Bosch, W., Heckmanb, M.G., Diehlb, N.N., Shalevc, J.A., Pungpapongd, S., Hellingera,
W.C., 2011. Association of cytomegalovirus infection and disease with death
and graft loss after liver transplant in high-risk recipients. Am. J. Transplant.
11 (10), 2181–2189.
Bresnahan, W.A., Boldogh, I., Thompson, E.A., Albrecht, T., 1996. Human cytome-
galovirus inhibits cellular DNA synthesis and arrests productively infected
cells in late G1. Virology 224 (1), 150–160.
Bruggeman, L.A., 2007. Viral subversion mechanisms in chronic kidney disease
pathogenesis. Clin. J. Am. Soc. Nephrol 2 (Suppl. 1), 13–19.
Cai, M.S., Li, M.L., Zheng, C.F., 2012. Herpesviral infection and Toll-like receptor 2.
Protein Cell 3 (8), 590–601.
Castillo, J.P., Kowalik, T.F., 2004. HCMV infection: modulating the cell cycle and
cell death. Int. Rev. Immunol. 23 (1–2), 113–139.
Cervera, C., Lozano, F., Saval, N., Gimferrer, I., Ibanez, A., Suarez, B., Linares, L., Cofan, F.,
Ricart, M.J., Esforzado, N., Marcos, M.A., Pumarola, T., Oppenheimer, F., Campistol,
J.M., Moreno, A., 2007. The inﬂuence of innate immunity gene receptors poly-
morphisms in renal transplantation infection. Transplantation 83 (11), 1493–1500.
Chang, W.L., Barry, P.A., 2010. Attenuation of innate immunity by cytomegalovirus
IL-10 establishes a long-term deﬁcit of adaptive antiviral immunity. Proc. Natl.
Acad. Sci. U.S.A 107 (52), 22647–22652.
Chiang, C.Y., Veckman, V., Limmer, K., David, M., 2011. Phospholipase Cg-2 and
intracellular calcium are required for lipopolysaccharide-induced Toll-like
receptor 4 (TLR4) endocytosis and interferon regulatory factor 3 (IRF3)
activation. J. Biol. Chem 287 (6), 3704–3709.
Cobbs, C.S., Harkins, L., Samanta, M., Gillespie, G.Y., Bharara, S., King, P.H., Nabors,
L.B., Cobbs, C.G., Britt, W.J., 2002. Human cytomegalovirus infection and
expression in human malignant glioma. Cancer Res. 62 (12), 3347–3350.
Compton, T., Kurt-Jones, E., Boheme, K.W., Belko, J., Latz, E., Golenbock, D.T.,
Finberg, R.W., 2003. Human cytomegalovirus activates inﬂammatory cytokine
responses via CD14 and toll-like receptor 2. J. Virol. 77 (8), 4588–4596.
Dittmer, D., Mocarski, E.S., 1997. Human cytomegalovirus infection inhibits G1/S
transition. J. Virol. 71 (2), 1629–1634.
Ducloux, D., Deschamps, M., Yannaraki, M., Ferrand, C., Bamoulid, J., Saas, P.,
Kazory, A., Chalopin, J.M., Tiberghien, P., 2005. Relevance of Toll-like receptor
4 polymorphisms in renal transplantation. Kidney Int. 67 (6), 2454–2461.
Fortunato, E.A., Sanchez, V., Yen, J.Y., Spector, D.H., 2002. Infection of cells with
human cytomegalovirus during S phase results in a blockade to immediate-
early gene expression that can be overcome by inhibition of the proteasome. J.
Virol 76 (11), 5369–5379.
Friboulet, L., Gourzones, C., Tsao, S.W., Morel, Y., Paturel, C., Temam, S., Uzan, C.,
Busson, P., 2010. Poly(I:C) induces intense expression of c-IAP2 and cooperates
with an IAP inhibitor in induction of apoptosis in cancer cells. BMC Cancer 10,
327–340.
Gale Jr., M., Tan, S.L., Katze, M.G., 2000. Translational control of viral gene
expression in eukaryotes. Microbiol. Mol. Biol. Rev. 64 (2), 239–280.
Gaur, P., Munjhal, A., Lal, S.K., 2011. Inﬂuenza virus and cell signaling pathways.
Med. Sci. Monit. 17 (6), 148–154.
Gobbi, G., Ricci, F., Malinverno, C., Carubbi, C., Pambianco, M., Panﬁlis, G., Vitale,
M., Mirandola, P., 2009. Hydrogen sulﬁde impairs keratinocyte cell growth and
adhesion inhibiting mitogen-activated protein kinase signaling. Lab. Invest. 89
(9), 994–1006.
Hagemeier, C., Caswell, R., Hayhurst, G., Sinclair, J., Kouzarides, T., 1994. Functional
interaction between the HCMV IE2 transactivator and the retinoblastoma
protein. EMBO J. 13 (12), 2897–2903.
Harwani, S.C., Lurain, N.S., Zariffard, M.R., Spear, G.T., 2007. Differential inhibition
of human cytomegalovirus (HCMV) by toll-like receptor ligands mediated by
interferon-beta in human foreskin ﬁbroblasts and cervical tissue. Virol. J 4,
133–142.
Hasan, A.U., Caux, C., Perrot, I., Dofﬁn, A.C., Menetrier-Caux, C., Trinchieri, G.,
Tommasino, M., Vlach, J., 2007. Cell proliferation and survival induced by
Toll-like receptors is antagonized by type one IFNs. Proc. Nat. Acad. Sci U.S.A
104 (19), 8047–8052.
Hasan, A.U., Trinchieri, G., Vlach, J., 2005. Toll-like receptor signaling stimulates
cell cycle entry and progression in ﬁbroblasts. J. Biol. Chem. 280 (21),
20620–20627.
Hertel, L., Mocarski, E.S., 2004. Global analysis of host cell gene expression late
during cytomegalovirus infection reveals extensive dysregulation of cell cycle
gene expression and induction of pseudomitosis independent of US28 function.
J. Virol 78 (21), 11988–12011.
Hornung, V., Rothenfusser, S., Britsch, S., Krug, A., Jahrsdo¨rfer, B., Giese, T., Endres,
S., Hartmann, G., 2002. Quantitative expression of toll-like receptor 1-10
mRNA in cellular subsets of human peripheral blood mononuclear cells and
sensitivity to CpG oligodeoxynucleotides. J. Immunol. 168 (9), 4531–4537.
Husebye, H., Halaas, O., Stenmark, H., Tunheim, G., Sandanger, O., Bogen, B., Brech,
A., Latz, E., Espevik, T., 2006. Endocytic pathways regulate Toll-like receptor
4 signaling and link innate and adaptive immunity. EMBO J. 25 (4), 683–692.Hwang, H.C., Clurman, B.E., 2005. Cyclin E in normal and neoplastic cell cycles.
Oncogene 24, 2776–2786.
Ioudinkova, E., Arcangeletti, M.C., Rynditch, A., De Conto, F., Motta, F., Covan, S.,
Pinardi, F., Razin, S.V., Chezzi, C., 2006. Control of human cytomegalovirus
gene expression by differential histone modiﬁcations during lytic and latent
infection of a monocytic cell line. Gene 384, 120–128.
Iversen, A.C., Steinkjer, B., Nilsen, N., Bohnhorst, J., Moen, S.H., Vik, R., Stephens, P.,
Thomas, D.W., Benedict, C.A., Espevik, T., 2009. A proviral role for CpG in
cytomegalovirus infection. J. Immunol. 182 (9), 5672–5681.
Jault, F.M., Jault, J.M., Ruchti, F., Fortunato, E.A., Clark, C., Corbeil, J., Richman, D.D.,
Spector, D.H., 1995. Cytomegalovirus infection induces high levels of cyclins,
phosphorylated Rb, and p53, leading to cell cycle arrest. J. Virol. 69 (11),
6697–6704.
Jiang, H., Wang, P.Z., Zhang, Y., Xu, Z., Sun, L., Wang, L.M., Huang, C.X., Lian, J.Q.,
Jia, Z.S., Li, Z.D., Bai, X.F., 2008. Hantaan virus induces toll-like receptor
4 expression, leading to enhanced production of beta interferon, interleukin-
6 and tumor necrosis factor-alpha. Virology 380 (1), 52–59.
Katayama, T., Nakanishi, K., Nishihara, H., Kamiyama, N., Nakagawa, T., Kamiyama,
T., Iseki, K., Tanaka, S., Todo, S., 2007. Type I interferon prolongs cell cycle
progression via p21WAF1/CIP1 induction in human colon cancer cells. Int. J.
Oncol. 31 (3), 613–620.
Kovacs, I.J., Hegedus, K., Pal, A., Pusztai, R., 2007. Production of proinﬂammatory
cytokines by syncytiotrophoblasts infected with human cytomegalovirus
isolates. Placenta 28 (7), 620–623.
Kurt-Jones, E.A., Chan, M., Zhou, S., Wang, J., Reed, G., Bronson, R., Arnold, M.M.,
Knipe, D.M., Finberg, R.W., 2004. Herpes simplex virus 1 interaction with
Toll-like receptor 2 contributes to lethal encephalitis. Proc. Natl. Acad. Sci.
U.S.A 101 (5), 1315–1320.
Lihn, A.S., Richelsen, B., Pedersen, S.B., Haugaard, S.B., Rathje, G.S., Madsbad, S.,
Andersen, O., 2003. Increased expression of TNF-a, IL-6, and IL-8 in HALS:im-
plications for reduced adiponectin expression and plasma levels. Am. J.
Physiol. Endocrinol. Metab. 285 (5), 1072–1080.
Lo¨fgren, J., Marttila, R., Renko, M., Ra¨met, M., Hallman, M., 2010. Toll-like receptor
4 Asp299Gly polymorphism in respiratory syncytial virus epidemics. Pediatr.
Pulmonol. 45 (7), 687–692.
Lunardi, C., Bason, C., Corrocher, R., Puccetti, A., 2005. Induction of endothelial cell
damage by HCMV molecular mimicry. Trends Immunol. 26 (1), 19–24.
Matsumoto, M., Kikkawa, S., Kohase, M., Miyake, K., Seyaa, T., 2002. Establishment
of a monoclonal antibody against human Toll-like receptor 3 that blocks
double-stranded RNA-mediated signaling. Biochem. Biophys. Res. Commun.
293 (5), 1364–1369.
Mendelson, M., Monard, S., Sissons, P., Sinclair, J., 1996. Detection of endogenous
human cytomegalovirus in CD34þ bone marrow progenitors. J. Gen. Virol. 77
(pt. 12), 3099–3102.
Mirandola, P., Sponzilli, I., Solenghi, E., Micheloni, C., Rinaldi, L., Gobbi, G., Vitale,
M., 2006. Down-regulation of human leukocyte antigen class I and II and beta
2-microglobulin expression in human herpesvirus-7-infected cells. J. Infect.
Dis. 193 (7), 917–926.
Mocarski, E.S., 2002a. Immunomodulation by cytomegaloviruses: manipulative
strategies beyond evasion. Trends. Microbiol. 10 (7), 332–339.
Mocarski, E.S., 2002b. Virus self-improvement through inﬂammation:no pain, no
gain. Proc. Nat. Acad. Sci. U.S.A. 99 (6), 3362–3364.
Mocarski, E.S., Courcelle, C.T., 2001. Cytomegalovirus and their replication. In:
Knipe, D., Howley, P. (Eds.), Fields Virology, fourth ed. Lippincott-Raven
Publishers, Philadelphia, pp. 2629–2673.
Opitz, B., Vinzing, M., van Laak, V., Schmeck, B., Heine, G., Gunther, S., Preissner, R.,
Slevogt, H., N’Guessan, P.D., Eitel, J., Goldmann, T., Flieger, A., Suttorp, N.,
Hippenstiel, S., 2006. Legionella pneumophila induces IFNb in lung epithelial
cells via IPS-1 and IRF3, which also control bacterial replication. J. Biol. Chem.
281 (47), 36173–36179.
Pagano, M., Pepperkok, R., Verde, F., Ansorge, W., Draetta, G., 1992. Cyclin A is
required at two points in the human cell cycle. EMBO J. 11 (3), 961–971.
Palazzo, M., Gariboldi, S., Zanobbio, L., Dusio, G.F., Selleri, S., Bedoni, M., Balsari, A.,
Rumio, C., 2008. Cross-talk among toll-like receptors and their ligands. Int.
Immunol. 20 (5), 709–718.
Pass, R.F., 2001. Cytomegalovirus. In: Knipe, D., Howley, P. (Eds.), Fields Virology,
fourth ed. Lippincott-Raven Publishers, Philadelphia, pp. 2575–2705.
Poma, E.E., Kowalik, T.F., Zhu, L., Sinclair, J.H., Huang, E.S., 1996. The human
cytomegalovirus IE1-72 protein interacts with the cellular p107 protein and
relieves p107-mediated transcriptional repression of an E2F-responsive pro-
moter. J. Virol 70 (11), 7867–7877.
Ramsay, M.E., Miller, E., Peckham, C.S., 1991. Outcome of conﬁrmed symptomatic
congenital cytomegalovirus infection. Arch. Dis. Child. 66 (9), 1068–1069.
Razonable, R.R., Paya, C.V., 2003. Herpesvirus infections in transplant recipients:
current challenges in the clinical management fo cytomegalovirus and
Epstein-Barr virus infections. Herpes 10 (3), 60–65.
Ro¨lle, A., Olweus, J., 2009. Dendritic cells in cytomegalovirus infection: viral
evasion and host countermeasures. A.P.M.I.S 117 (5–6), 413–426.
Rudd, B.D., Burstein, E., Duckett, C.S., Li, X., Lukacs, N.W., 2005. Differential role for
TLR3 in respiratory syncytial virus-induced chemokine expression. J. Virol. 79
(6), 3350–3357.
Salsman, J., Jagannathan, M., Paladino, P., Chan, P.K., Dellaire, G., Raught, B.,
Frappier, L., 2012. Proteomic proﬁling of the human cytomegalovirus UL35
gene products reveals a role for UL35 in the DNA repair response. J. Virol. 86
(2), 806–820.
M.-C. Arcangeletti et al. / Virology 440 (2013) 19–3030Sinclair, J., Baillie, J., Bryant, L., Caswell, R., 2000. Human cytomegalovirus
mediates cell cycle progression through G1 into early S phase in terminally
differentiated cells. J. Gen. Virol. 81 (pt.6), 1553–1565.
Sinclair, J., Sissons, P., 2006. Latency and reactivation of human citomegalovirus. J.
Gen. Virol. 87 (pt. 7), 1763–1779.
Slobedman, B., Stern, J.L., Cunningham, A.L., Abendroth, A., Abate, D.A., Mocarski, E.S.,
2004. Impact of human cytomegalovirus latent infection onmyeloid progenitor cell
gene expression. J. Virol. 78 (8), 4054–4062.
Smith, M.S., Bentz, G.L., Alexander, J.S., Yurochko, A.D., 2004. Human cytomega-
lovirus induces monocyte differentiation and migration as a strategy for
dissemination and persistence. J. Virol. 78 (9), 4444–4453.
So¨derberg-Naucle´r, C., Streblow, D.N., Fish, K.N., Allan-Yorke, J., Smith, P.P., Nelson, J.A.,
2001. Reactivation of latent human cytomegalovirus in CD14(þ) monocytes is
differentiation dependent. J. Virol. 75 (16), 7543–7554.
Song, Y.J., Stinski, M.F., 2005. Inhibition of cell division by the human cytomega-
lovirus IE86 protein: role of the p53 pathway or cyclin-dependent kinase
1/cyclin B1. J. Virol 79 (4), 2597–2603.
Taylor-Wiedeman, J., Sissons, P., Sinclair, J., 1994. Induction of endogenous human
cytomegalovirus gene expression after differentiation of monocytes from
healthy carriers. J. Virol 68 (3), 1597–1604.
Varani, S., Landini, M.P., 2011. Cytomegalovirus-induced immunopathology and its
clinical consequences. Herpesviridae 2 (1), 6–20.Vermeulen, K., Van Bockstaele, D.R., Berneman, Z.N., 2003. The cell cycle: a review
of regulation, deregulation and therapeutic targets in cancer. Cell Prolif. 36,
131–149.
West, J., Damania, B., 2008. Upregulation of the TLR3 pathway by Kaposi’s
sarcoma-associated herpesvirus during primary infection. J. Virol 82 (11),
5440–5449.
Wiebusch, L., Asmar, J., Uecker, R., Hagemeier, C., 2003. Human cytomegalovirus
immediate-early protein 2 (IE2)-mediated activation of cyclin E is cell-cycle-
independent and forces S-phase entry in IE2-arrested cells. J. Gen. Virol 84 (pt 1),
51–60.
Wolf, J., Weinberger, B., Grubeck-Loebenstein, B., 2012. The immunoregulatory
effects of CMV infection in human ﬁbroblasts and the impact on cellular
senescence. Immun. Ageing 9, 1–6.
Xagorari, A., Chlichlia, K., 2008. Toll-like receptors and viruses: induction of innate
antiviral immune responses. Open Microbiol. J 2, 49–59.
Xia, C., Lu, M., Zhang, Z., Meng, Z., Zhang, Z., Shi, C., 2008. TLRs antiviral effect on
hepatitis B virus in HepG2 cells. J. Appl. Microbiol. 105 (5), 1720–1727.
Zanoni, I., Ostuni, R., Marek, L.R., Barresi, S., Barbalat, R., Barton, G.M., Granucci, F.,
Kagan, J.C., 2011. CD14 controls the LPS-induced endocytosis of Toll-like
receptor 4. Cell 147 (4), 868–880.
Zarember, K.A., Godowski, P.J., 2002. Tissue expression of human Toll-like
receptors and differential regulation of toll-like receptor mRNA in leukocytes
in response to microbes, their production, and cytokines. J. Immunol 168 (2),
554–561.
